STAT

STAT Plus: Pharmalittle: BioNTech expects to seek approval for vaccine by year-end; why the FDA chose a 50% threshold for Covid-19 vaccines

Peter Marks, a top FDA official, shed light on the reasoning behind the agency's choice of a 50% efficacy threshold for a Covid-19 vaccine.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks